Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 3 , Pages 201-206 , May 2007

Magnetic resonance imaging of bone metastases in patients with nonseminomatous germ cell tumors

  • Michael Froehner, M.D.

      Affiliations

    • Department of Urology, University Hospital “Carl Gustav Carus,” Technical University of Dresden, Dresden, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49-351-4582447; fax: +49-351-4584333.
    • ,
  • Peter Aikele, M.D.

      Affiliations

    • Department of Radiology, University Hospital “Carl Gustav Carus,” Technical University of Dresden, Dresden, Germany
    • ,
  • Bettina Beuthien-Baumann, M.D.

      Affiliations

    • Department of Nuclear Medicine and PET Center Rossendorf, University Hospital “Carl Gustav Carus,” Technical University of Dresden, Dresden, Germany
    • ,
  • Thomas Kittner, M.D.

      Affiliations

    • Department of Radiology, University Hospital “Carl Gustav Carus,” Technical University of Dresden, Dresden, Germany
    • ,
  • Sven Oehlschlaeger, M.D.

      Affiliations

    • Department of Urology, University Hospital “Carl Gustav Carus,” Technical University of Dresden, Dresden, Germany
    • ,
  • Manfred P. Wirth, M.D.

      Affiliations

    • Department of Urology, University Hospital “Carl Gustav Carus,” Technical University of Dresden, Dresden, Germany

Received 2 May 2006 ,Revised 26 June 2006 ,Accepted 14 July 2006.

References 

  1. Clamp A, Danson S, Nguyen H, et al. Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol. 2004;5:607–616
  2. Tombal B, Rezazadeh A, Therasse P, et al. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate. 2005;65:178–187
  3. Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942–2953
  4. ESMO Guidelines Task ForceHuddart RA, Purkalne G. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumors (NSGCT). Ann Oncol. 2005;16(Suppl 1):i37–i39
  5. Laguna MP, Pizzocaro G, Klepp O, et al. EAU guidelines on testicular cancer. Eur Urol. 2001;40:102–110
  6. Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer. Eur Urol. 2005;48:885–894
  7. German Testicular Cancer Study GroupSouchon R, Schmoll HJ, Krege S. Leitlinie zur diagnostik und therapie von hodentumoren auf grundlage evidenzbasierter medizin (EBM). 1st ed.. München (Germany): W. Zuckschwerdt; 2002;
  8. Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol. 2004;15:1377–1399
  9. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15:594–603
  10. Braga FJ, Arbex MA, Haddad J, et al. Bone scintigraphy in testicular tumors. Clin Nucl Med. 2001;26:117–118
  11. Bredael JJ, Vugrin D, Whitmore WF. Autopsy findings in 154 patients with germ cell tumors of the testis. Cancer. 1982;50:548–551
  12. Bauer HCF. Controversies in the surgical management of skeletal metastases. J Bone Joint Surg. 2005;87:608–617-B
  13. Turner JW, Hawes DR, Williams RD. Magnetic resonance imaging for detection of prostate cancer metastatic to bone. J Urol. 1993;149:1482–1484

PII: S1078-1439(06)00239-0

doi: 10.1016/j.urolonc.2006.07.017

Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 3 , Pages 201-206 , May 2007

Article Tools

* Image Usage & Resolution